MX2019000252A - Administracion viral oncolitica pseudotipada de polipeptidos terapeuticos. - Google Patents
Administracion viral oncolitica pseudotipada de polipeptidos terapeuticos.Info
- Publication number
- MX2019000252A MX2019000252A MX2019000252A MX2019000252A MX2019000252A MX 2019000252 A MX2019000252 A MX 2019000252A MX 2019000252 A MX2019000252 A MX 2019000252A MX 2019000252 A MX2019000252 A MX 2019000252A MX 2019000252 A MX2019000252 A MX 2019000252A
- Authority
- MX
- Mexico
- Prior art keywords
- pseudotyped oncolytic
- viral delivery
- therapeutic polypeptides
- oncolytic viral
- pseudotyped
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
- C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5443—IL-15
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6489—Metalloendopeptidases (3.4.24)
- C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16633—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16641—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20241—Use of virus, viral particle or viral elements as a vector
- C12N2760/20243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
En el presente documento se describen virus oncolíticos pseudotipados que comprenden ácidos nucleicos que codifican una molécula de engrane. En algunas realizaciones, los virus oncolíticos pseudotipados comprenden ácidos nucleicos que codifican una molécula activa y una o más moléculas terapéuticas. Las composiciones farmacéuticas que contienen el virus oncolítico pseudotipado y los métodos para tratar el cáncer usando los virus oncolíticos pseudotipados se proporcionan adicionalmente en este documento.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662357195P | 2016-06-30 | 2016-06-30 | |
PCT/US2017/040354 WO2018006005A1 (en) | 2016-06-30 | 2017-06-30 | Pseudotyped oncolytic viral delivery of therapeutic polypeptides |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019000252A true MX2019000252A (es) | 2019-10-09 |
Family
ID=60787595
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019000252A MX2019000252A (es) | 2016-06-30 | 2017-06-30 | Administracion viral oncolitica pseudotipada de polipeptidos terapeuticos. |
Country Status (13)
Country | Link |
---|---|
US (3) | US20180057594A1 (es) |
EP (1) | EP3478321A4 (es) |
JP (3) | JP2019519245A (es) |
KR (1) | KR20190035714A (es) |
CN (1) | CN109983121A (es) |
AU (1) | AU2017290828A1 (es) |
BR (1) | BR112019000015A2 (es) |
CA (1) | CA3029426A1 (es) |
IL (2) | IL263879B (es) |
MX (1) | MX2019000252A (es) |
RU (2) | RU2021127872A (es) |
SG (1) | SG11201811600PA (es) |
WO (1) | WO2018006005A1 (es) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10888549B2 (en) | 2016-03-07 | 2021-01-12 | The Johns Hopkins University | Pharmaceutical agents targeting cancer stem cells |
SG11201811600PA (en) | 2016-06-30 | 2019-01-30 | Oncorus Inc | Pseudotyped oncolytic viral delivery of therapeutic polypeptides |
AU2018273958B2 (en) | 2017-05-25 | 2022-07-21 | Leidos, Inc. | PD-1 and CTLA-4 dual inhibitor peptides |
CN111212656A (zh) * | 2017-07-26 | 2020-05-29 | 昂克诺斯公司 | 溶瘤病毒载体及其用途 |
HUE058233T2 (hu) | 2017-08-03 | 2022-07-28 | Amgen Inc | Interleukin-21-muteinek és kezelési eljárások |
SG11202001499WA (en) | 2017-09-08 | 2020-03-30 | Amgen Inc | Inhibitors of kras g12c and methods of using the same |
US11865081B2 (en) | 2017-12-29 | 2024-01-09 | Virogin Biotech Canada Ltd. | Oncolytic viral delivery of therapeutic polypeptides |
CR20200330A (es) | 2018-01-12 | 2020-12-23 | Amgen Inc | Anticuerpos anti-pd-1 y métodos de tratamiento |
KR20200143689A (ko) * | 2018-04-15 | 2020-12-24 | 살루브리스 (청두) 바이오테크 코., 리미티드 | Pd-1 결합 항체 및 그의 용도 |
KR102558418B1 (ko) * | 2018-04-15 | 2023-07-24 | 임비라 컴퍼니 리미티드 | Pd-1에 결합하는 항체 및 그 용도 |
CN108727504B (zh) * | 2018-04-16 | 2021-08-27 | 泉州向日葵生物科技有限公司 | 一种ifn与抗pd-l1抗体的融合蛋白及其应用 |
CA3106143A1 (en) | 2018-07-11 | 2020-01-16 | Actym Therapeutics, Inc. | Engineered immunostimulatory bacterial strains and uses thereof |
CN110819657B (zh) * | 2018-08-10 | 2021-11-19 | 睿丰康生物医药科技(浙江)有限公司 | 一种减毒棒状病毒的制备方法及应用 |
JP2022507269A (ja) * | 2018-11-13 | 2022-01-18 | オンコラス, インコーポレイテッド | カプセル化ポリヌクレオチド及び使用方法 |
BR112021009929B1 (pt) | 2018-11-21 | 2023-10-03 | Mayo Foundation For Medical Education And Research | Adenovírus recombinante, composição farmacêutica compreendendo o mesmo e seus usos para tratamento de câncer |
TW202039835A (zh) | 2018-12-27 | 2020-11-01 | 美商安進公司 | 凍乾病毒配製物 |
JP2022516318A (ja) * | 2019-01-04 | 2022-02-25 | オンコラス, インコーポレイテッド | カプセル化ポリヌクレオチド及び使用方法 |
US20200246420A1 (en) * | 2019-01-28 | 2020-08-06 | Rhode Island Council On Postsecondary Education | pHLIP® peptide-mediated epitope tethering at cell surfaces |
US20220098324A1 (en) * | 2019-01-30 | 2022-03-31 | The Wistar Institute Of Anatomy And Biology | Dna-encoded bispecific t-cell engagers targeting cancer antigens and methods of use in cancer theraputics |
CN113748124A (zh) | 2019-02-27 | 2021-12-03 | 阿克蒂姆治疗有限公司 | 工程化以定植肿瘤、肿瘤驻留免疫细胞和肿瘤微环境的免疫刺激性细菌 |
JP2022522817A (ja) | 2019-03-05 | 2022-04-20 | アムジエン・インコーポレーテツド | がんを治療するための腫瘍溶解性ウイルスの使用 |
TW202102543A (zh) | 2019-03-29 | 2021-01-16 | 美商安進公司 | 溶瘤病毒在癌症新輔助療法中之用途 |
JP7381604B2 (ja) * | 2019-04-29 | 2023-11-15 | メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ | 癌を治療するための多価pd-l1結合化合物 |
EP3972696A1 (en) | 2019-05-22 | 2022-03-30 | Leidos, Inc. | Lag3 binding peptides |
DE112020002641T9 (de) * | 2019-05-31 | 2022-10-06 | Guangzhou Virotech Pharmaceutical Co., Ltd. | M1-Virusmutante und deren Verwendung |
US20220280609A1 (en) * | 2019-07-17 | 2022-09-08 | The Regents Of The University Of California | Combination cancer therapy agents and methods |
EP4041256A4 (en) * | 2019-10-10 | 2023-11-08 | Arizona Board of Regents on behalf of Arizona State University | MULTI-SPECIFIC IMMUNE CELL-ENGAGERS EXPRESSING ONCOLYTIC VIRUSES |
IL292836A (en) | 2019-11-12 | 2022-07-01 | Actym Therapeutics Inc | Platforms for administering bacteria that stimulate the immune system and their use for administering therapeutic products |
US20230227549A1 (en) * | 2020-02-07 | 2023-07-20 | City Of Hope | Oncolytic virus compositions and methods for the treatment of cancer |
CN111759841A (zh) * | 2020-06-03 | 2020-10-13 | 山西第三医学研究发展有限公司 | 一种用匹多莫德在抗新型冠状病毒感染中的应用 |
US20210386804A1 (en) * | 2020-06-11 | 2021-12-16 | Tibor Bakács | Combination of viral superinfection therapy with subthreshold doses of nivolumab plus ipilimumab in chronic HBV patients |
CN113832114A (zh) * | 2020-06-23 | 2021-12-24 | 南京大学 | 一种新型溶瘤腺病毒EM/VSV-G Ad5-P及其在制备抗肿瘤药物中的应用 |
AU2021316230A1 (en) | 2020-07-31 | 2023-03-16 | Leidos, Inc. | LAG3 binding peptides |
EP4196139A2 (en) | 2020-08-12 | 2023-06-21 | Actym Therapeutics, Inc. | Immunostimulatory bacteria-based vaccines, therapeutics, and rna delivery platforms |
CN112143711B (zh) * | 2020-09-29 | 2021-07-23 | 杭州荣谷生物科技有限公司 | 重组痘瘤病毒、药物组合物及其构建方法和应用 |
JP2023548662A (ja) | 2020-10-12 | 2023-11-20 | レイドス, インコーポレイテッド | 免疫調節性ペプチド |
WO2022148736A1 (en) * | 2021-01-05 | 2022-07-14 | Transgene | Vectorization of muc1 t cell engager |
CN112840020B (zh) * | 2021-01-13 | 2023-03-17 | 嘉兴允英医学检验有限公司 | 溶瘤病毒及其应用 |
EP4319782A1 (en) * | 2021-04-05 | 2024-02-14 | Implicyte, Inc. | Armed chimeric oncolytic viruses |
CN113969266B (zh) * | 2021-10-26 | 2023-10-13 | 山东大学齐鲁医院 | 一种重组溶瘤腺病毒及其应用 |
CN113980915B (zh) * | 2021-11-04 | 2023-07-07 | 江苏省人民医院(南京医科大学第一附属医院) | 一种新型的表达cxcl10的复制型溶瘤腺病毒和应用 |
CA3235418A1 (en) | 2021-11-09 | 2023-05-19 | Actym Therapeutics, Inc. | Immunostimulatory bacteria for converting macrophages into a phenotype amenable to treatment, and companion diagnostic for identifying subjects for treatment |
CN114249836A (zh) * | 2021-12-27 | 2022-03-29 | 上海鑫湾生物科技有限公司 | 双特异性t细胞衔接器、其重组溶瘤病毒及其用途 |
WO2023235596A1 (en) * | 2022-06-03 | 2023-12-07 | 10X Genomics, Inc. | Systems and methods for determining antigen binding specificity of antigen binding molecules |
WO2024067540A1 (en) * | 2022-09-30 | 2024-04-04 | Immvira Biopharmaceuticals Co., Limited | Genetically engineered herpes simplex virus type 1 for treatment of hematologic cancers |
Family Cites Families (125)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4476116A (en) | 1982-12-10 | 1984-10-09 | Syntex (U.S.A.) Inc. | Polypeptides/chelating agent nasal compositions having enhanced peptide absorption |
US5116817A (en) | 1982-12-10 | 1992-05-26 | Syntex (U.S.A.) Inc. | LHRH preparations for intranasal administration |
US5244792A (en) | 1984-04-06 | 1993-09-14 | Chiron Corporation | Expression of recombinant glyoprotein B from herpes simplex virus |
JPH0668B2 (ja) | 1985-08-30 | 1994-01-05 | 財団法人化学及血清療法研究所 | 単純ヘルペスウイルス遺伝子が組込まれた組換えプラスミド |
US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
US5804413A (en) | 1992-07-31 | 1998-09-08 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Herpes simplex virus strains for gene transfer |
US6084067A (en) | 1993-07-26 | 2000-07-04 | Dana-Farber Cancer Institute | CTLA4/CD28 ligands and uses therefor |
GB9415369D0 (en) | 1994-07-29 | 1994-09-21 | Lynxvale Ltd | Mutant virus |
US5855887A (en) | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
US5898031A (en) | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
US6071742A (en) | 1997-03-05 | 2000-06-06 | Board Of Regents Of The University Of Nebraska | Coxsackie virus as a vector for delivery of anti-inflammatory cytokines |
WO1998040475A1 (en) | 1997-03-11 | 1998-09-17 | Abbott Laboratories | Human matrix metalloprotease gene, proteins encoded therefrom and methods of using same |
WO1998042752A1 (en) | 1997-03-21 | 1998-10-01 | Brigham And Women's Hospital Inc. | Immunotherapeutic ctla-4 binding peptides |
US6391452B1 (en) | 1997-07-18 | 2002-05-21 | Bayer Corporation | Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations |
AU8605598A (en) | 1997-07-31 | 1999-02-22 | University Of Pittsburgh | Targeted hsv vectors |
US6989435B2 (en) | 1997-09-11 | 2006-01-24 | Cambridge University Technical Services Ltd. | Compounds and methods to inhibit or augment an inflammatory response |
ATE305510T1 (de) | 1997-12-17 | 2005-10-15 | Immunex Corp | Zelloberflächenglycoproteinen zusammenhang mit menschlicher b zell lymphomen - ulbp, dns und polypeptiden |
US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
ES2203141T3 (es) | 1998-04-21 | 2004-04-01 | Micromet Ag | Polipeptidos cd19 x cd3 especificos y su utilizacion. |
US6455677B1 (en) | 1998-04-30 | 2002-09-24 | Boehringer Ingelheim International Gmbh | FAPα-specific antibody with improved producibility |
EP0953639A1 (en) | 1998-04-30 | 1999-11-03 | Boehringer Ingelheim International GmbH | FAPalpha-specific antibody with improved producibility |
EP1002864A1 (en) | 1998-11-10 | 2000-05-24 | Universita' degli studi di Bologna | HIgR and related V domain for the manufacture of a medicament for preventing or treating HSV-1, HSV-2 and BHV infections |
US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
NZ512553A (en) | 1998-12-23 | 2004-02-27 | Pfizer | Human monoclonal antibodies to cytotoxic T lymphocyte antigen 4 (CTLA-4) |
US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
KR100942863B1 (ko) | 1999-08-24 | 2010-02-17 | 메다렉스, 인코포레이티드 | 인간 씨티엘에이-4 항체 및 그의 용도 |
US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
US6897057B1 (en) | 1999-08-31 | 2005-05-24 | The General Hospital Corporation | Cell-specific and/or tumor-specific promoter retargeting of herpes γ 34.5 gene expression |
AU1086501A (en) | 1999-10-15 | 2001-04-30 | Carnegie Institution Of Washington | Rna interference pathway genes as tools for targeted genetic interference |
EP1261376A1 (en) | 2000-01-27 | 2002-12-04 | Genetics Institute, LLC | Antibodies against ctla4(cd152), conjugates comprising same, and uses thereof |
JP2003530092A (ja) | 2000-03-17 | 2003-10-14 | ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | ヒトFAP−α−特異抗体 |
CA2404890C (en) | 2000-03-30 | 2013-11-19 | Whitehead Institute For Biomedical Research | Rna sequence-specific mediators of rna interference |
BRPI0115814B8 (pt) | 2000-12-01 | 2021-05-25 | Europaeisches Laboratorium Fuer Molekularbiologie Embl | moléculas de rna de filamento duplo, seu método de preparação e composição farmacêutica compreendendo as mesmas |
AU2002306919B2 (en) | 2001-03-27 | 2007-11-22 | Tomoki Todo | Viral vectors and their use in therapeutic methods |
DE60232742D1 (de) | 2001-10-04 | 2009-08-06 | Immunex Corp | Ul16-bindungsprotein 4 |
KR100900249B1 (ko) | 2001-12-07 | 2009-05-29 | 포항공과대학교 산학협력단 | SIVmac239의 면역원성 플라스미드 및 이들을 함유한AIDS DNA 백신 |
NZ536420A (en) | 2002-04-12 | 2008-04-30 | Medarex Inc | Methods of treatment using CTLA-4 antibodies |
DE10161767T1 (de) | 2002-07-03 | 2018-06-07 | Honjo Tasuku | Immunopotenzierende Zusammensetzungen, die einen Anti-PD-L1 Antikörper enthalten |
US8927251B2 (en) | 2002-10-07 | 2015-01-06 | The University Of Chicago | Targeting of herpes simplex virus to specific receptors |
KR100944575B1 (ko) | 2002-10-17 | 2010-02-25 | 젠맵 에이/에스 | Cd20에 대한 인간 모노클로날 항체 |
EP2270051B1 (en) * | 2003-01-23 | 2019-05-15 | Ono Pharmaceutical Co., Ltd. | Antibody specific for human PD-1 and CD3 |
CA2517287C (en) | 2003-02-28 | 2022-12-13 | The Johns Hopkins University | Regulation of t cells by lag-3 (cd223) |
WO2004081021A2 (en) | 2003-03-12 | 2004-09-23 | Duke University | Oligonucleotide mimetics |
US7473418B2 (en) | 2004-03-25 | 2009-01-06 | Cell Genesys, Inc. | Pan cancer oncolytic vectors and methods of use thereof |
EP1732600A2 (en) | 2004-03-26 | 2006-12-20 | Pfizer Products Incorporated | Uses of anti-ctla-4 antibodies |
KR101295733B1 (ko) | 2004-08-20 | 2013-08-13 | 비랄리틱스 리미티드 | 혈액암의 치료방법 및 조성물 |
US20090252741A1 (en) | 2004-09-08 | 2009-10-08 | Ohio State University Research Foundation | Human monoclonal anti-ctla4 antibodies in cancer treatment |
WO2006050211A2 (en) | 2004-10-28 | 2006-05-11 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Peripherally delivered glutamic acid decarboxylase gene therapy for spinal cord injury pain |
WO2006074526A1 (en) | 2005-01-17 | 2006-07-20 | Viralytics Limited | Method and composition for treatment of neoplasms |
US10000757B2 (en) | 2005-05-27 | 2018-06-19 | Ospedale San Raffaele S.R.L. | Gene vector |
SI1907000T2 (sl) | 2005-06-08 | 2020-07-31 | Dana-Farber Cancer Institute | Postopki in sestavki za zdravljenje persistentne HIV infekcije z inhibicijo programiranih celični smrtnih 1 (PD-1) poti |
HUE026039T2 (en) | 2005-07-01 | 2016-05-30 | Squibb & Sons Llc | Human monoclonal antibodies programmed for death ligand 1 (PD-L1) |
US8980246B2 (en) | 2005-09-07 | 2015-03-17 | Sillajen Biotherapeutics, Inc. | Oncolytic vaccinia virus cancer therapy |
RU2008129080A (ru) | 2005-12-16 | 2010-01-27 | Микромет Аг (De) | Средства и способы лечения опухолевых заболеваний |
CA2633713A1 (en) | 2005-12-21 | 2007-06-28 | Micromet Ag | Epha2 bite molecules and uses thereof |
EP1806365A1 (en) | 2006-01-05 | 2007-07-11 | Boehringer Ingelheim International GmbH | Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them |
JP6092497B2 (ja) | 2006-03-30 | 2017-03-08 | ユニバーシティー オブ カリフォルニア | 抗ctla−4抗体の限局性分泌のための方法および組成物 |
AU2007266306A1 (en) | 2006-05-26 | 2007-12-06 | Apollo Life Sciences Limited | An isolated IL-12 molecule or chimeric molecules thereof |
CN101104640A (zh) | 2006-07-10 | 2008-01-16 | 苏州大学 | 抗人pd-l1单克隆抗体制备及应用 |
JP2008066402A (ja) | 2006-09-05 | 2008-03-21 | Fujifilm Corp | 撮像素子および撮像装置 |
EP2064229B1 (en) * | 2006-09-15 | 2015-08-12 | Ottawa Hospital Research Institute | Oncolytic rhabdovirus |
US20100111873A1 (en) | 2007-02-20 | 2010-05-06 | Russell Stephen J | Treating cancer with viral nucleic acid |
EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
WO2008134878A1 (en) * | 2007-05-04 | 2008-11-13 | University Health Network | Compositions and methods for cancer treatment |
EP2144632B1 (en) | 2007-05-09 | 2016-11-16 | Board of Supervisors of Louisiana State University and Agricultural and Mechanical College | Synthetic herpes simplex viruses type-1 for treatment of cancers |
CA2703947C (en) | 2007-10-26 | 2018-12-04 | Governing Council Of The University Of Toronto | Therapeutic and diagnostic methods using tim-3 |
WO2009100140A1 (en) | 2008-02-04 | 2009-08-13 | Medarex, Inc. | Anti-clta-4 antibodies with reduced blocking of binding of ctla-4 to b7 and uses thereof |
WO2009111892A1 (en) | 2008-03-14 | 2009-09-17 | Ottawa Health Research Institute | Microrna mediated oncolytic targeting |
PT2700405T (pt) | 2008-05-29 | 2018-05-02 | Univ Bologna Alma Mater Studiorum | Vírus herpes simplex (hsv) com tropismo modificado, suas utilizações e processo de preparação |
EP2307033A4 (en) | 2008-05-29 | 2012-06-13 | Gen Hospital Corp | USE OF ONCOLYTIC HERPESVIRUS FOR THE KILLING OF CANCER STEM CELLS |
GB0810912D0 (en) | 2008-06-13 | 2008-07-23 | Inst Animal Health Ltd | Vector |
AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
KR102097887B1 (ko) | 2008-09-26 | 2020-04-06 | 다나-파버 캔서 인스티튜트 인크. | 인간 항-pd-1, pd-l1, 및 pd-l2 항체 및 그의 용도 |
CN114835812A (zh) | 2008-12-09 | 2022-08-02 | 霍夫曼-拉罗奇有限公司 | 抗-pd-l1抗体及它们用于增强t细胞功能的用途 |
EP3192811A1 (en) | 2009-02-09 | 2017-07-19 | Université d'Aix-Marseille | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
AU2010223888A1 (en) | 2009-03-13 | 2011-10-06 | Egen, Inc. | Compositions and methods for the delivery of biologically active RNAs |
ES2385251B1 (es) * | 2009-05-06 | 2013-05-06 | Fundació Privada Institut D'investigació Biomèdica De Bellvitge | Adenovirus oncolíticos para el tratamiento del cáncer. |
US20100297072A1 (en) | 2009-05-19 | 2010-11-25 | Depinho Ronald A | Combinations of Immunostimulatory Agents, Oncolytic Virus, and Additional Anticancer Therapy |
AU2011237630B2 (en) | 2010-04-06 | 2016-01-21 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of CD274/PD-L1 gene |
CA2795695A1 (en) | 2010-04-09 | 2011-10-13 | The University Of Tokyo | Microrna-controlled recombinant vaccinia virus and use thereof |
WO2011130749A2 (en) | 2010-04-16 | 2011-10-20 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Identification of mutations in herpes simplex virus envelope glycoproteins that enable or enhance vector retargeting to novel non-hsv receptors |
CA2802344C (en) | 2010-06-18 | 2023-06-13 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions |
WO2012006181A2 (en) | 2010-06-29 | 2012-01-12 | Mount Sinai School Of Medicine | Compositions and methods for inhibiting oncogenic micrornas and treatment of cancer |
MY175341A (en) | 2010-08-13 | 2020-06-19 | Roche Glycart Ag | Anti-fap antibodies and methods of use |
GB201103955D0 (en) | 2011-03-09 | 2011-04-20 | Antitope Ltd | Antibodies |
RU2625034C2 (ru) | 2011-04-20 | 2017-07-11 | МЕДИММЬЮН, ЭлЭлСи | Антитела и другие молекулы, которые связывают в7-н1 и pd-1 |
WO2013006490A2 (en) | 2011-07-01 | 2013-01-10 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to tim3 |
ES2704632T3 (es) * | 2011-09-08 | 2019-03-19 | Univ New York | Virus de herpes simplex oncolítico y sus usos terapéuticos |
EP2591796A1 (en) | 2011-11-10 | 2013-05-15 | Universität Zürich | Combination medicament comprising IL-12 and an anti-CTLA-4 ligand for tumor therapy |
US11951157B2 (en) | 2011-10-11 | 2024-04-09 | Universitat Zurich | Methods of treating malignant tumour with IL-12 and anti-PD-1 antibody |
AU2012322999B2 (en) | 2011-10-11 | 2017-08-10 | Universitat Zurich Prorektorat Mnw | Combination medicament comprising IL-12 and an agent for blockade of T-cell inhibitory molecules for tumour therapy |
SI2768524T1 (sl) | 2011-10-17 | 2022-09-30 | Io Biotech Aps | Imunoterapija na osnovi PD-L1 |
US20130156808A1 (en) | 2011-11-22 | 2013-06-20 | Stipan Jonjic | Vaccine comprising beta-herpesvirus |
AU2012344260B2 (en) | 2011-11-28 | 2017-09-07 | Merck Patent Gmbh | Anti-PD-L1 antibodies and uses thereof |
CN104427992B (zh) | 2012-01-25 | 2017-12-19 | 德那翠丝有限公司 | 生物标志物及使用溶瘤病毒和免疫调节剂的组合疗法 |
CN115093480A (zh) | 2012-05-31 | 2022-09-23 | 索伦托药业有限公司 | 与pd-l1结合的抗原结合蛋白 |
WO2014047350A1 (en) * | 2012-09-20 | 2014-03-27 | Morningside Technology Ventures Ltd. | Oncolytic virus encoding pd-1 binding agents and uses of the same |
US9365641B2 (en) | 2012-10-01 | 2016-06-14 | The Trustees Of The University Of Pennsylvania | Compositions and methods for targeting stromal cells for the treatment of cancer |
CN105407902A (zh) * | 2013-03-05 | 2016-03-16 | 贝勒医学院 | 溶瘤病毒 |
ES2681948T3 (es) * | 2013-03-05 | 2018-09-17 | Baylor College Of Medicine | Células de acoplamiento para inmunoterapia |
US9308236B2 (en) | 2013-03-15 | 2016-04-12 | Bristol-Myers Squibb Company | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions |
UA118028C2 (uk) | 2013-04-03 | 2018-11-12 | Рош Глікарт Аг | Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування |
KR20210084651A (ko) | 2013-04-18 | 2021-07-07 | 틸트 바이오세러퓨틱스 오이 | 향상된 입양 세포 치료 |
US20160163211A1 (en) | 2013-05-16 | 2016-06-09 | Pearson Education, Inc. | Accessible content publishing engine |
DK3184641T3 (da) | 2013-10-28 | 2020-08-03 | Univ Of Pittsburgh - Of The Commonwealth System Of Higher Education | Onkolytisk hsv-vektor |
KR102407019B1 (ko) | 2014-02-27 | 2022-06-08 | 머크 샤프 앤드 돔 코포레이션 | 암의 치료를 위한 결합 방법 |
HUE045108T2 (hu) * | 2014-07-16 | 2019-12-30 | Transgene Sa | Onkolitikus vírus immunellenõrzõpont-modulátorok expresszálására |
WO2016055432A2 (en) | 2014-10-08 | 2016-04-14 | F. Hoffmann-La Roche Ag | Combination therapy of bispecific antibodies specific for fap and dr5 and chemotherapeutic agents |
CN107614522A (zh) * | 2015-01-14 | 2018-01-19 | 指南针制药有限责任公司 | 多特异性免疫调节性抗原结合构建体 |
CN108135934A (zh) | 2015-10-19 | 2018-06-08 | 永恒生物科技股份有限公司 | 通过组合疗法治疗实体或淋巴肿瘤的方法 |
WO2017103291A1 (en) * | 2015-12-17 | 2017-06-22 | Psioxus Therapeutics Limited | Virus encoding an anti-tcr-complex antibody or fragment |
JP7038664B2 (ja) * | 2016-01-08 | 2022-03-18 | レプリミュン リミテッド | 操作された腫瘍溶解性ウイルス |
JP2019508063A (ja) | 2016-01-27 | 2019-03-28 | オンコラス, インコーポレイテッド | 腫瘍溶解性ウイルスベクター及びその使用 |
EP3426271A4 (en) | 2016-03-10 | 2019-10-16 | Cold Genesys, Inc. | METHODS OF TREATING SOLID OR LYMPHATIC TUMORS BY POLYTHERAPY |
SG11201811600PA (en) | 2016-06-30 | 2019-01-30 | Oncorus Inc | Pseudotyped oncolytic viral delivery of therapeutic polypeptides |
WO2018026872A1 (en) | 2016-08-01 | 2018-02-08 | Virogin Biotech Canada Ltd | Oncolytic herpes simplex virus vectors expressing immune system-stimulatory molecules |
EP3497208A4 (en) | 2016-08-09 | 2020-03-11 | Turnstone Limited Partnership | ONCOLYTIC RHABDOVIRUS EXPRESSING IL12 |
TW201825674A (zh) | 2016-09-09 | 2018-07-16 | 美商艾斯合顧問有限公司 | 表現雙特異性接合分子的溶瘤病毒 |
CN110072550A (zh) | 2016-11-01 | 2019-07-30 | 德那翠丝有限公司 | 用于治疗脑癌的组合疗法 |
US11298420B2 (en) | 2016-12-21 | 2022-04-12 | Memgen, Llc | Armed oncolytic viruses |
AU2017379835A1 (en) | 2016-12-21 | 2019-07-11 | Dnatrix | Armed replication-competent oncolytic adenoviruses |
GB201700350D0 (en) | 2017-01-09 | 2017-02-22 | Replimune Ltd | Altered virus |
US11865081B2 (en) | 2017-12-29 | 2024-01-09 | Virogin Biotech Canada Ltd. | Oncolytic viral delivery of therapeutic polypeptides |
-
2017
- 2017-06-30 SG SG11201811600PA patent/SG11201811600PA/en unknown
- 2017-06-30 AU AU2017290828A patent/AU2017290828A1/en active Pending
- 2017-06-30 RU RU2021127872A patent/RU2021127872A/ru unknown
- 2017-06-30 CN CN201780051486.3A patent/CN109983121A/zh active Pending
- 2017-06-30 MX MX2019000252A patent/MX2019000252A/es unknown
- 2017-06-30 KR KR1020197002887A patent/KR20190035714A/ko not_active Application Discontinuation
- 2017-06-30 WO PCT/US2017/040354 patent/WO2018006005A1/en unknown
- 2017-06-30 RU RU2019102391A patent/RU2758007C2/ru active
- 2017-06-30 JP JP2018568903A patent/JP2019519245A/ja not_active Withdrawn
- 2017-06-30 CA CA3029426A patent/CA3029426A1/en active Pending
- 2017-06-30 EP EP17821384.9A patent/EP3478321A4/en active Pending
- 2017-06-30 BR BR112019000015-1A patent/BR112019000015A2/pt unknown
- 2017-09-29 US US15/720,696 patent/US20180057594A1/en not_active Abandoned
-
2018
- 2018-10-25 US US16/170,764 patent/US10604574B2/en active Active
- 2018-12-20 IL IL263879A patent/IL263879B/en active IP Right Grant
-
2020
- 2020-01-28 US US16/775,164 patent/US11078280B2/en active Active
-
2021
- 2021-04-11 IL IL282216A patent/IL282216A/en unknown
-
2022
- 2022-02-02 JP JP2022014714A patent/JP2022048304A/ja not_active Withdrawn
-
2023
- 2023-10-20 JP JP2023181009A patent/JP2023174945A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2017290828A1 (en) | 2019-01-24 |
EP3478321A1 (en) | 2019-05-08 |
WO2018006005A1 (en) | 2018-01-04 |
KR20190035714A (ko) | 2019-04-03 |
US11078280B2 (en) | 2021-08-03 |
JP2023174945A (ja) | 2023-12-08 |
CN109983121A (zh) | 2019-07-05 |
SG11201811600PA (en) | 2019-01-30 |
RU2019102391A (ru) | 2020-07-30 |
JP2022048304A (ja) | 2022-03-25 |
IL263879B (en) | 2021-04-29 |
RU2758007C2 (ru) | 2021-10-25 |
US20180057594A1 (en) | 2018-03-01 |
EP3478321A4 (en) | 2020-04-22 |
US10604574B2 (en) | 2020-03-31 |
US20200157221A1 (en) | 2020-05-21 |
IL263879A (en) | 2019-01-31 |
BR112019000015A2 (pt) | 2019-04-24 |
IL282216A (en) | 2021-05-31 |
RU2021127872A (ru) | 2021-11-09 |
RU2019102391A3 (es) | 2021-01-26 |
US20190048082A1 (en) | 2019-02-14 |
JP2019519245A (ja) | 2019-07-11 |
CA3029426A1 (en) | 2018-01-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2019000252A (es) | Administracion viral oncolitica pseudotipada de polipeptidos terapeuticos. | |
BR112018013930A2 (pt) | vírus oncolítico, vírus que expressa três genes heterólogos, composição farmacêutica, vírus para o uso, produto de fabricação, método de tratamento de câncer e uso do vírus | |
PH12017501942A1 (en) | Oncolytic adenovirus encoding a b7 protein | |
BR112019001737A2 (pt) | expressão de pten-long com vírus oncolíticos | |
CY1124157T1 (el) | Προσδετες δικυκλικου πεπτιδιου ειδικοι για μτ1-mmρ | |
CL2019000392A1 (es) | Métodos para detectar aav. | |
SA518400424B1 (ar) | جزيئات الجسم المضاد لعلاج السرطان | |
BR112018011711A2 (pt) | peptídeos de direcionamento para direcionar virus adeno-associados (aav) | |
CY1123697T1 (el) | Θεραπεια της amd με χρηση της παραλλαγης aav2 με αφλιβερσεπτη | |
MX2022006652A (es) | Proteinas de capside modificadas para un suministro mejorado de vectores de parvovirus. | |
BR112018073238A2 (pt) | vírus oncolíticos compreendendo esrage e métodos de tratamento de câncer | |
WO2015109124A3 (en) | Immunomodulatory agents | |
WO2016183366A3 (en) | Compositions and methods for silencing expression of hepatitis d virus rna | |
EA201691891A1 (ru) | Генная терапия для лечения пигментного ретинита | |
CL2019003842A1 (es) | Vectores virales recombinantes con tropismo modificado y usos de estos para la introducción dirigida de material genético a células humanas. | |
WO2014055836A3 (en) | Serine protease molecules and therapies | |
MX2021008146A (es) | Polinucleotidos de arn encapsulado y metodos de uso. | |
MY194289A (en) | Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, and Methods of use | |
AU2018273963A1 (en) | Novel oncolytic viruses for sensitizing tumor cells to killing by natural killer cells | |
EA202090700A1 (ru) | Компетентные по репликации аденовирусные векторы | |
MX2021005980A (es) | Adenovirus y metodos para usar adenovirus. | |
TW201612190A (en) | Flavivirus virus like particle | |
WO2018057502A3 (en) | Molecular verification systems | |
WO2015123592A3 (en) | Recombinant rna particles and methods of use | |
BR112019005825A2 (pt) | vírus envelopado modificado, composição farmacêutica, e, método para tratar um câncer |